Marrow blasts from children with B cell precursor acute lymphoblastic leukemia (ALL) were studied for differences in quantitative expression of the common ALL antigen (CALLA). Of 42 untreated patients, 35 had detectable amounts of CALLA by flow cytometric (FCM) analysis of J-5 monoclonal antibody binding. Using an FCM technique that provides correlated measurements of a given cell surface antigen, cell size, and DNA content, we detected increased CALLA expression as lymphoblasts moved from G0/G1 phase through S phase of the cell cycle. The density of the antigen (per unit of blast surface area) remained relatively constant over the same interval, indicating that the change was not due to S phase-specific enhancement of CALLA expression. Eight cases had hyperdiploid cellular DNA content and in seven of these, only cells with clonal abnormalities of DNA content expressed the CALLA marker. Mean amounts of CALLA for each patient ranged widely within the study group, from very high to marginally detectable. This variation had no discernible relation to cell size, stem-line DNA content, percentage of cells in S phase, or the presence or absence of cytoplasmic immunoglobulin. Results of a univariate proportional hazards analysis showed that both quantitative level of CALLA for S phase cells (P = 0.048) and white blood cell count (P = 0.012) had made significant contributions to treatment outcome. Patients […] 
As bstract. Marrow blasts from children with B cell precursor acute lymphoblastic leukemia (ALL) were studied for differences in quantitative expression of the common ALL antigen (CALLA). Of 42 untreated patients, 35 had detectable amounts of CALLA by flow cytometric (FCM) analysis of J-5 monoclonal antibody binding. Using an FCM technique that provides correlated measurements of a given cell surface antigen, cell size, and DNA content, we detected increased CALLA expression as lymphoblasts moved from GO/GI phase through S phase of the cell cycle. The density of the antigen (per unit of blast surface area) remained relatively constant over the same interval, indicating that the change was not due to S phase-specific enhancement of CALLA expression. Eight cases had hyperdiploid cellular DNA content and in seven of these, only cells with clonal abnormalities of DNA content expressed the CALLA marker. Mean amounts ofCALLA for each patient ranged widely within the study group, from very high to marginally detectable. This variation had no discernible relation to cell size, stem-line DNA content, percentage of cells in S phase, or the presence or absence of cytoplasmic immunoglobulin. Results of a univariate proportional hazards analysis showed that both quantitative level of CALLA for S phase cells (P = 0.048) and white blood cell count (P = 0.012) had made significant contributions to treatment outcome. Patients with relative amounts of CALLA less than the median value for the entire CALLA' group had a higher rate of failure, which was virtually identical to that for the seven HLA-DR' patients whose blasts lacked detectable CALLA. The observed interpa-
Introduction
The common acute lymphoblastic leukemia antigen (CALLA, also gplOO),' which was discovered by Greaves et al. (1) , is present on the blasts of most children with ALL and has been linked to a favorable prognosis (2) (3) (4) (5) . Detection of CALLA on leukemic cells was followed by recognition ofa small population (1-10%) of normal lymphoid precursors that also express the antigen, indicating that it is a marker of normal lymphoid cell differentiation (6) (7) (8) (9) . Biochemical studies have identified CALLA as a cell-surface glycoprotein of 100,000 D (10) (11) (12) , and monoclonal antibodies to the molecule have been developed ( 13, 14) .
Korsmeyer et al. (15) recently found rearranged Ig genes and selective expression of surface antigens in 25 cases of socalled non-T, non-B ALL, which comprises the majority of cases of ALL in children. They interpreted this as evidence that such cases result from monoclonal expansion ofB cell precursors representing serial stages of Ig gene rearrangement and surface antigen expression. In their scheme, the earliest precursors bear only HLA-DR antigens, whereas cells with rearranged light chain genes possess both HLA-DR and CALLA. These findings prompted us to adopt the term "B cell precursor ALL" for cases that lack features of mature T or B cells and have either an HLA-DR+, CALLA-or HLA-DR+, CALLA+ phenotype.
We reasoned from studies with other differentiation antigens (16) (17) (18) (19) (20) that quantitation of CALLA on leukemic blasts might disclose substantial differences in its expression, which could be related to the predicted pattern of differentiation within the B precursor pathway (15) . Additionally, since about one-third of children with a CALLA phenotype relapse within 2 yr of diagnosis (2) (3) (4) (5) their treatment responses showed no appreciable deviation from those of the study group (P = 0.5). A summary of presenting clinical and laboratory features can be found in Table II .
All 42 patients with B cell precursor ALL were treated by St. Jude Total Therapy Study X protocol, which makes provision for two cateiories ofrisk assignment (22, 23 Immediately before FCM analysis, cells were stained for DNA with propidium iodide using a modification of the method of Crissman and Steinkamp (25) . Cells in ethanol were pelleted and resuspended in 5 ml of cold PBS. Ribonuclease (50 #Lg/ml; bovine pancreas, CalbiochemBehring, Corp., La Jolla, CA) was added to the cell suspension, which was then incubated for 30 min at room temperature. Cells were pelleted and resuspended in 1 ml of PBS containing 0.05 mg/ml propidium iodide (Calbiochem-Behring Corp.) at 40C. Just before FCM analysis, the stained cell suspensions were filtered through 37- (26) . In practice, the high voltage ofthe green photomultiplier was set at 900, and the differential amplifier was adjusted so that the signal from an aliquot of cells stained only with propidium iodide was orthogonal to the red fluorescence axis of the two-parameter red and green fluorescence display on the MDADS minicomputer (Coulter Electronics, Inc.). The gain of the green fluorescence could then be adjusted to center the J-5 green fluorescence on a linear scale for each patient, since the effect of the differential amplifier is independent of the gain setting. The cells stained with the UPC10 monoclone were then analyzed at the same gain setting as the cells stained for the J-5 monoclone. Forward-angle light scatter (1-19°) Table I . The results represent testing intervals that coincide with those in clinical investigations. FCM analysis ofDNA content ofstained nuclei. An aliquot of marrow cells from each patient was stained directly with hypotonic propidium iodide citrate solution (27) , and cellular DNA content distributions obtained with this technique were compared with those derived from cell populations stained with both fluorescein and propidium iodide after fixation. DNA content histograms of marrow blasts were analyzed for DNA index, coefficient of variation of the Go/GI phase leukemic cells, and the percentage of S phase cells, as previously described (28).
Leukemia cellphenotype. Cells from these patients were also examined for the presence of HLA-DR molecules by use of the 12 monoclonal antibody (29) (provided by Dr. Lee Nadler and Dr. Stuart Schlossman, Division of Tumor Immunology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School). The assay for cytoplasmic Ig (CIg) was performed by a published method (30) .
Centrifugal elutriation. The NALM-1 cells were separated according to size by centrifugal elutriation at 4VC in a Beckman J-21C centrifuge (Beckman Instruments, Inc., Palo Alto, CA) equipped with a JE-6 elutriator rotor exactly as described (31). Seven fractions, 100 ml each, were collected at flow rates of 5.0-9.0 ml/min. The first fraction was discarded because it contained mainly debris and dead cells. Cells in each fraction were collected by centrifugation and resuspended in cold PBS. The mean cell diameter of each fraction was determined with an Elzone 8OXY particle counter (Particle Data, Inc., Elmhurst, IL). Mean forward-angle light scatter was determined by FCM for viable cells and ethanol-fixed cells that had been resuspended in PBS.
Statistical analysis. All statistical procedures except those related to disease-free survival were done with the Minitab computing system (32); specific tests are identified in the Results section. Times to failure, as of July 1, 1983, were plotted by the Kaplan-Meier method (33) , and the resulting curves compared by the log-rank test (34) . Time to failure was defined as the interval between achievement of remission and relapse or death due to any cause. Patients who failed to enter remission were assigned a failure time of zero. The influence of potential prognostic factors on outcome was estimated with the proportional hazards model of Cox (35) . Each factor was considered as a single regression variable, and those achieving significance were analyzed in combination.
Results
Phenotypic markers and DNA content. CALLA was detectable with the J-5 monoclonal antibody only on marrow blasts from 35 of the 42 patients with B cell precursor ALL, nine of whom had cells positive for CIg, a phenotypic marker of pre-B cell ALL (30) . In two cases, CALLA+ blasts failed to react with the 12 antibody; both were CIg+, and in one, the cells reacted with a heterologous anti-HLA-DR antiserum. The distribution of clinical features and cell markers among CALLA+ patients (Table  II) was similar to findings in other series (2) (3) (4) (5) and to those for our seven HLA-DR+, CALLA-patients.
DNA content abnormalities, determined by FCM analysis, were apparent in marrow blasts from eight CALLA+ patients: seven had single hyperdiploid leukemic stem lines (median DNA index of 1.20, range 1.14-2.0) and one had tetraploid and hypotetraploid lines in addition to a diploid line. Increased cellular DNA content was also found in cells of two patients with CALLA-B precursor ALL. Fig. 2 A, and were evident in both the S and G2 + M phases of the cell cycle as well as GO/GI (Fig. 2 B) . By contrast, the CALLA' Fig. 1 (Fig. 3) , as was noted for the other six hyperdiploid cases. In the second case, however, the diploid GO/GI cells contained both CALLA' and CALLA-cells (Fig. 4) (Fig. 7 ). Using this relationship as a basis for calculating the surface area of patients' blasts, we were able to show that, despite a progressive increase in CALLA-associated fluorescence per cell from GO/GI through S phase (Fig. 8 A) , CALLA density remained relatively constant (Fig. 8 B) . Interpatient variation of CALLA expression. Mean relative CALLA expression by leukemic blasts varied widely among the 35 patients, from very high to marginally detectable (Fig. 9) terminations on S phase, GO/GI phase, and combined cell populations. With a median time to failure or last follow-up of 20 mo (range 0-28 mo), the greatest difference in remission duration (P = 0.058) was found between groups identified by S phase CALLA above or below 9.4 relative units (Fig. 10) . After 12 mo of therapy, the time-to-failure curve for patients with lower amounts of S phase CALLA was nearly identical to that for the CALLA-group. To refine our analysis, we sought cutoff points that might yield greater statistical significance in a comparison of times to failure. The findings were 9.6 relative units for S phase CALLA (P = 0.03) and 9.4 for GO/GI phase CALLA (P = 0.09). Thus, even with values giving maximal separation, S phase CALLA provided the most reliable prediction of treatment outcome.
Certain clinical and laboratory features have been closely linked to disease-free survival in ALL (2-5); hence, we analyzed potential prognostic factors using the Cox proportional hazards model (Table III) . Aside from quantitative level of S phase CALLA (P = 0.048), only log WBC achieved significance (P = 0.012). The model predicted a threefold greater relative risk of relapse for patients with lower S phase CALLA, even after adjustment for WBC. A combination of lower S phase CALLA and higher WBC was associated with a 14-fold greater risk of failure than was the opposite combination. The gain in prognostic information obtained by combining S phase CALLA with WBC can be readily appreciated from the Kaplan-Meier analysis depicted in Fig. 11 . Discussion ALL appears to be the result of clonal expansion oftransformed lymphoid progenitor cells unable to complete normal differentiation programs. By studying the expression of certain differentiation-linked molecules on leukemic cells, it has been possible to classify most cases of ALL into broad subcategories that correspond to stages of normal lymphoid cell development (2) . Within the B cell precursor series, for instance, patterns of phenotypic markers uniformly include HLA-DR and over half include CALLA (2) (3) (4) (5) 14) . In previous studies of the immunologically defined subclasses of ALL (2) (3) (4) (5) The wide interpatient variation in CALLA expression could not be attributed to factors with potential biological influence (e.g., cell size, stem-line DNA content, or percentage of cells in S phase). Rather, it appears to reflect the coordinate sequence of B cell precursor differentiation proposed by Korsmeyer et dl. (15) . In their model, all cells with recombined light and heavy chain Ig genes express both CALLA and HLA-DR, whereas cells with only rearranged heavy chain genes express HLA-DR with or without detectable CALLA. In view of the wide quan'-titative variation of CALLA expression revealed by FCM analysis, we propose that cases with only heavy chain gene rear- In each of the 35 CALLA+ cases, the antigen was detected on G0/G1-phase as well as S phase blasts, demonstrating that its presence does not depend on cell cycle phase. Nonetheless, we recorded appreciable increases of CALLA as blasts moved from GO/GI into S. Unlike the kinetics of several other cell surface antigens, including HLA-DR (18) (19) (20) , this change does not appear to be under independent cell cycle control, as the net increase of CALLA in S phase corresponded approximately to increased cell size (surface area). GO/G1 reflects an increased uniformity ofCALLA measurement within this well-defined region ofthe cell cycle. Flow cytometric analysis of DNA content does not distinguish Go and GI phase cells from each other. In view of the importance of S phase cells in the growth and therapeutic response ofleukemic cell populations, the characteristics of this subpopulation may furnish the most valuable information for predicting treatment outcome.
The versatility of FCM analysis has not been fully exploited in the measurement ofantigens on leukemic cells. In any scheme of the sequential acquisition of surface antigens with differentiation, the influence of quantitative variation in the amount of antigen expressed and the lower limit of detection by the methods employed must be considered (16, 17) . The flow cytometer is the ideal instrument with which to quantitate monoclonal antibody binding to specific surface markers expressed by leukemic cells in concert with other important cellular features. The next logical step is to use new multilaser FCM systems to assess the extent of differentiation within a leukemic cell population by simultaneously measuring the quantitative expression of multiple differentiation markers in addition to cell size and cell cycle phase (38, 39) .
